Rituximab is a medication that works by targeting specific cells in your immune system called B cells. It is commonly used to treat certain autoimmune conditions and some types of blood cancers. In this trial, it is being studied as a treatment for Minimal Change Nephrotic Syndrome (MCNS), a kidney condition that causes protein loss in urine. The medication is given through an intravenous infusion (directly into the vein) and is being tested to see if it can prevent the disease from coming back after initial treatment.

Steroids are medications that help reduce inflammation and suppress the immune system. In this trial, they are used as part of the initial treatment for MCNS, and the researchers are studying how to gradually stop steroid treatment while using Rituximab to prevent the disease from returning.

Minimal Change Nephrotic Syndrome – A kidney condition characterized by excessive protein loss in urine, leading to low protein levels in blood and swelling in various parts of the body. The disease gets its name because kidney tissue appears nearly normal under a regular microscope, showing only minimal changes when examined with an electron microscope. The condition causes the tiny filters in the kidneys (glomeruli) to become more permeable, allowing proteins to leak from blood into urine. It commonly results in significant swelling (edema), particularly around the eyes, feet, and ankles. The condition can occur as single episodes or may follow a relapsing-remitting pattern over time.